金吾财讯 | 吉利德科学(GILD)公布首季财报,按年扭亏为盈,录季度纯利13.15亿美元,对上财年同季录亏损41.7亿美元,主要涉及研发减值24.3亿美元及收购正进行研发所涉开支41.31亿美元拖累。季度每股摊薄纯利1.04美元,经调整后为1.81美元,略高于市场预期的1.79美元。季度收入按年跌不足1%至66.67亿美元,市场预期为68亿美元。公司爱滋病药Biktarvy销售按年升7%至31.5亿美元,符合市场预期。肝病药销售按年升3%至7.58亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.